Samia J Khoury

List of Publications by Year
in descending order

177	16,148	30551 56	18944 123
papers	citations	h-index	g-index

186	186	186	21800
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): Validation in Arabic and Lebanese Normative Values. Journal of the International Neuropsychological Society, 2022, 28, 94-103.	1.2	7
2	Central vein sign: A putative diagnostic marker for multiple sclerosis. Acta Neurologica Scandinavica, 2022, 145, 279-287.	1.0	3
3	The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 869-876.	0.7	4
4	Domestic tethers: Gender differences in career paths and domestic responsibilities of top-research medical school graduates. PLoS ONE, 2022, 17, e0267288.	1.1	2
5	Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 62, 103793.	0.9	3
6	Rare Case of Spinal Neurosarcoidosis with Concomitant Epidural Lipomatosis. Case Reports in Neurological Medicine, 2021, 2021, 1-6.	0.3	2
7	Exosomes From Subjects With Multiple Sclerosis Express EBV-Derived Proteins and Activate Monocyte-Derived Macrophages. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1004.	3.1	14
8	Effect of fingolimod vs interferon treatment on OCT measurements and cognitive function in RRMS. Multiple Sclerosis and Related Disorders, 2021, 53, 103041.	0.9	9
9	Long-term cognitive deficits after traumatic brain injury associated with microglia activation. Clinical Immunology, 2021, 230, 108815.	1.4	12
10	Opposite functions of STAT3 and Smad3 in regulating Tiam1 expression in Th17 cells. Small GTPases, 2020, 11, 62-68.	0.7	3
11	Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Multiple Sclerosis and Related Disorders, 2020, 37, 101459.	0.9	56
12	â€œNo evidence of disease activityâ€: Is it an aspirational therapeutic goal in multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2020, 40, 101935.	0.9	17
13	<scp>SARSâ€CoV</scp>â€2 and Multiple Sclerosis: Not All Immune Depleting <scp>DMTs</scp> are Equal or Bad. Annals of Neurology, 2020, 87, 794-797.	2.8	45
14	Development, psychometric properties, and pilot norms of the first Arabic indigenous memory test: The Verbal Memory Arabic Test (VMAT). Journal of Clinical and Experimental Neuropsychology, 2020, 42, 505-515.	0.8	7
15	Progressive Multiple Sclerosis. Annals of Neurology, 2020, 88, 436-437.	2.8	3
16	Multiple sclerosis in the Middle East and North Africa region. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521731989554.	0.5	1
17	Serum vitamin D level is associated with speed of processing in multiple sclerosis patients. Journal of Steroid Biochemistry and Molecular Biology, 2020, 200, 105628.	1.2	5
18	Mental health research in the Arab region: challenges and call for action. Lancet Psychiatry,the, 2019, 6, 961-966.	3.7	58

#	Article	IF	Citations
19	Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance. Journal of Immunology, 2019, 202, 1373-1382.	0.4	46
20	Risk of relapses during pregnancy among multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2019, 34, 9-13.	0.9	25
21	Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents. Critical Reviews in Toxicology, 2019, 49, 262-279.	1.9	33
22	Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation. Nature Communications, 2019, 10, 217.	5.8	56
23	Gadoterate Meglumine Administration in Multiple Sclerosis has no Effect on the Dentate Nucleus and the Globus Pallidus Signal Intensities. Academic Radiology, 2019, 26, e284-e291.	1.3	5
24	Co-signaling Molecules in Neurological Diseases. Advances in Experimental Medicine and Biology, 2019, 1189, 233-265.	0.8	4
25	Foxo1 Promotes Th9 Cell Differentiation and Airway Allergy. Scientific Reports, 2018, 8, 818.	1.6	24
26	Effectiveness of alternative dose fingolimod for multiple sclerosis. Neurology: Clinical Practice, 2018, 8, 102-107.	0.8	10
27	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Multiple Sclerosis Journal, 2018, 24, 1485-1498.	1.4	19
28	Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study. Journal of Immunology Research, 2018, 2018, 1-9.	0.9	44
29	The Bayesian risk estimate at onset (BREMSO) correlates with cognitive and physical disability in patients with early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 26, 96-102.	0.9	1
30	Efficacy and safety of natalizumab extended interval dosing. Multiple Sclerosis and Related Disorders, 2018, 24, 113-116.	0.9	45
31	Identification of MS-specific serum miRNAs in an international multicenter study. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e491.	3.1	59
32	Gadolinium effect on thalamus and whole brain tissue segmentation. Neuroradiology, 2018, 60, 1167-1173.	1.1	5
33	Effect of vitamin D replacement on immunological biomarkers in patients with multiple sclerosis. Clinical Immunology, 2017, 181, 9-15.	1.4	13
34	Effect of Vitamin D Replacement on Cognition in Multiple Sclerosis Patients. Scientific Reports, 2017, 7, 45926.	1.6	37
35	Defects in CD4+ T cell LFA-1 integrin-dependent adhesion and proliferation protect Cd47â^'/â^' mice from EAE. Journal of Leukocyte Biology, 2017, 101, 493-505.	1.5	13
36	Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis. Journal of the Neurological Sciences, 2017, 380, 79-81.	0.3	7

#	Article	IF	Citations
37	Th9 cells in the pathogenesis of EAE and multiple sclerosis. Seminars in Immunopathology, 2017, 39, 79-87.	2.8	56
38	Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases. Neurotherapeutics, 2017, 14, 135-147.	2.1	13
39	ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 686-695.	1.4	47
40	Medical Research Volunteer Program (MRVP): innovative program promoting undergraduate research in the medical field. BMC Medical Education, 2016, 16, 160.	1.0	19
41	Comparative effect of 25(OH)D3 and 1,25(OH)2D3 on Th17 cell differentiation. Clinical Immunology, 2016, 166-167, 59-71.	1.4	50
42	Imaging in multiple sclerosis: A new spin on lesions. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 577-586.	0.9	8
43	Retinal measures correlate with cognitive and physical disability in early multiple sclerosis. Journal of Neurology, 2016, 263, 2287-2295.	1.8	20
44	Three cases of herpes zoster radiculitis in MS patients treated with natalizumab. Multiple Sclerosis and Related Disorders, 2016, 9, 122-124.	0.9	4
45	Tiam1/Rac1 complex controls Il17a transcription and autoimmunity. Nature Communications, 2016, 7, 13048.	5.8	38
46	JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study. Journal of the Neurological Sciences, 2016, 360, 61-65.	0.3	24
47	Rheumatoid arthritis-associated RBPJ polymorphism alters memory CD4⁺T cells. Human Molecular Genetics, 2016, 25, 404-417.	1.4	8
48	Serum 25-hydroxyvitamin D predicts cognitive performance in adults. Neuropsychiatric Disease and Treatment, 2015, 11, 2217.	1.0	38
49	Safety and efficacy of reduced fingolimod dosage treatment. Journal of Neuroimmunology, 2015, 285, 13-15.	1.1	23
50	Cell surface glycan engineering of neural stem cells augments neurotropism and improves recovery in a murine model of multiple sclerosis. Glycobiology, 2015, 25, 1392-1409.	1.3	49
51	Risk factors for multiple sclerosis and associations with anti-EBV antibody titers. Clinical Immunology, 2015, 158, 59-66.	1.4	23
52	Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East. Journal of Neuroimmunology, 2015, 289, 93-97.	1.1	24
53	Role of CD47 in CD4+ T cell Proliferation after TCR Stimulation. FASEB Journal, 2015, 29, 285.3.	0.2	0
54	Effect of Natalizumab Treatment on Circulating Plasmacytoid Dendritic Cells: A Cross-Sectional Observational Study in Patients with Multiple Sclerosis. PLoS ONE, 2014, 9, e103716.	1.1	10

#	Article	IF	Citations
55	Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Multiple Sclerosis Journal, 2014, 20, 438-444.	1.4	36
56	BCL6 Controls Th9 Cell Development by Repressing Il9 Transcription. Journal of Immunology, 2014, 193, 198-207.	0.4	45
57	Increased Th17 response to myelin peptides in pediatric MS. Clinical Immunology, 2013, 146, 176-184.	1.4	30
58	No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurology, 2013, 13, 73.	0.8	26
59	Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurology, 2013, 13, 172.	0.8	27
60	Sex influences in autoimmune disease. Clinical Immunology, 2013, 149, 169.	1.4	1
61	Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis. Annals of Neurology, 2013, 73, 729-740.	2.8	214
62	IL-4 and Retinoic Acid Synergistically Induce Regulatory Dendritic Cells Expressing Aldh1a2. Journal of Immunology, 2013, 191, 3139-3151.	0.4	44
63	An RNA Profile Identifies Two Subsets of Multiple Sclerosis Patients Differing in Disease Activity. Science Translational Medicine, 2012, 4, 153ra131.	5.8	56
64	Galectin-1 Deactivates Classically Activated Microglia and Protects from Inflammation-Induced Neurodegeneration. Immunity, 2012, 37, 249-263.	6.6	313
65	Robust tumor immunity to melanoma mediated by interleukin-9â€“producing T cells. Nature Medicine, 2012, 18, 1248-1253.	15.2	368
66	Notch Receptors and Smad3 Signaling Cooperate in the Induction of Interleukin-9-Producing T Cells. Immunity, 2012, 36, 623-634.	6.6	135
67	Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: A longitudinal study. Journal of the Neurological Sciences, 2012, 315, 49-54.	0.3	16
68	Type17 T-cells in Central Nervous System Autoimmunity and Tumors. Journal of Clinical Immunology, 2012, 32, 802-808.	2.0	26
69	Immunopathogenesis of multiple sclerosis. Clinical Immunology, 2012, 142, 2-8.	1.4	128
70	Therapeutic strategies in multiple sclerosis. Clinical Immunology, 2012, 142, 1.	1.4	1
71	Immune modulation by Lacto-N-fucopentaose III in experimental autoimmune encephalomyelitis. Clinical Immunology, 2012, 142, 351-361.	1.4	50
72	The Relationship between Normal Cerebral Perfusion Patterns and White Matter Lesion Distribution in 1,249 Patients with Multiple Sclerosis. Journal of Neuroimaging, 2012, 22, 129-136.	1.0	68

#	Article	IF	Citations
73	Neuroimmunology. , 2012, , 735-755.		0
74	Plasticity of Ly-6Chi Myeloid Cells in T Cell Regulation. Journal of Immunology, 2011, 187, 2418-2432.	0.4	58
75	Subventricular zone microglia transcriptional networks. Brain, Behavior, and Immunity, 2011, 25, 991-999.	2.0	14
76	Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis. Neurology Research International, 2011, 2011, 1-6.	0.5	23
77	Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis. , 2011, 21, e50-e56.		98
78	HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes and Immunity, 2011, 12, 183-190.	2.2	16
79	Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments. Journal of Neuroimmunology, 2011, 233, 168-174.	1.1	41
80	Reversible neural stem cell niche dysfunction in a model of multiple sclerosis. Annals of Neurology, 2011, 69, 878-891.	2.8	72
81	Multimodal coherent anti-Stokes Raman scattering microscopy reveals microglia-associated myelin and axonal dysfunction in multiple sclerosis-like lesions in mice. Journal of Biomedical Optics, 2011, 16, 021109.	1.4	65
82	Notch Ligand Delta-Like 4 Blockade Alleviates Experimental Autoimmune Encephalomyelitis by Promoting Regulatory T Cell Development. Journal of Immunology, 2011, 187, 2322-2328.	0.4	77
83	Oral Administration of OKT3 Monoclonal Antibody to Human Subjects Induces a Dose-Dependent Immunologic Effect in T Cells and Dendritic Cells. Journal of Clinical Immunology, 2010, 30, 167-177.	2.0	69
84	Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis. Annals of Neurology, 2010, 68, 778-779.	2.8	18
85	A Randomized Controlled Double-Masked Trial of Albuterol Add-on Therapy in Patients With Multiple Sclerosis. Archives of Neurology, 2010, 67, 1055-61.	4.9	45
86	A Putative Alzheimer's Disease Risk Allele in PCK1 Influences Brain Atrophy in Multiple Sclerosis. PLoS ONE, 2010, 5, e14169.	1.1	20
87	TGF-Î² Induces IL-9 Production from Human Th17 Cells. Journal of Immunology, 2010, 185, 46-54.	0.4	152
88	CD200R1 Agonist Attenuates Mechanisms of Chronic Disease in a Murine Model of Multiple Sclerosis. Journal of Neuroscience, 2010, 30, 2025-2038.	1.7	71
89	Daclizumab in treatment of multiple sclerosis patients. Multiple Sclerosis Journal, 2009, 15, 272-274.	1.4	31
90	Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis. Journal of Immunology, 2009, 183, 4067-4076.	0.4	182

#	Article	IF	Citations
91	Rate of Brain Atrophy in Benign vs Early Multiple Sclerosis. Archives of Neurology, 2009, 66, 234-7.	4.9	43
92	Smoking and Disease Progression in Multiple Sclerosis. Archives of Neurology, 2009, 66, 858-64.	4.9	182
93	IL-9 induces differentiation of T _H 17 cells and enhances function of FoxP3 ⁺ natural regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12885-12890.	3.3	428
94	A tale of two STAT6 knock out mice in the induction of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2009, 206, 76-85.	1.1	9
95	Localizing central nervous system immune surveillance: Meningeal antigenâ€presenting cells activate T cells during experimental autoimmune encephalomyelitis. Annals of Neurology, 2009, 65, 457-469.	2.8	230
96	Deep Gray Matter Involvement on Brain MRI Scans Is Associated with Clinical Progression in Multiple Sclerosis. Journal of Neuroimaging, 2009, 19, 3-8.	1.0	114
97	Paradoxical dysregulation of the neural stem cell pathway sonic hedgehogâ€gli1 in autoimmune encephalomyelitis and multiple sclerosis. Annals of Neurology, 2008, 64, 417-427.	2.8	92
98	IL-4 inhibits TGF-Î²-induced Foxp3+ T cells and, together with TGF-Î², generates IL-9+ IL-10+ Foxp3â^' effector T cells. Nature Immunology, 2008, 9, 1347-1355.	7.0	980
99	F.29. The Activation Status of Inflammatory Monocytes Determines Their Immune Regulatory Function. Clinical Immunology, 2008, 127, S52.	1.4	0
100	Immunotherapy for neurological diseases. Clinical Immunology, 2008, 128, 294-305.	1.4	51
101	Distinct Functions of Autoreactive Memory and Effector CD4+ T Cells in Experimental Autoimmune Encephalomyelitis. American Journal of Pathology, 2008, 173, 411-422.	1.9	59
102	Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain, 2008, 131, 2564-2578.	3.7	228
103	Predicting Clinical Progression in Multiple Sclerosis With the Magnetic Resonance Disease Severity Scale. Archives of Neurology, 2008, 65, 1449.	4.9	53
104	Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain, 2008, 131, 1701-1711.	3.7	73
105	Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18889-18894.	3.3	231
106	Neural Stem Cells and the Future Treatment of Neurological Diseases: Raising the Standard. Methods in Molecular Biology, 2008, 438, 9-16.	0.4	7
107	Neuroimmunology. , 2008, , 807-829.		1
108	Jagged1 and Delta1 Differentially Regulate the Outcome of Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2007, 179, 5990-5998.	0.4	97

#	Article	IF	Citations
109	Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. Journal of Experimental Medicine, 2007, 204, 1691-1702.	4.2	117
110	Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsingâ€“remitting experimental autoimmune encephalomyelitis. Brain, 2007, 130, 2816-2829.	3.7	148
111	Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 1004-1010.	1.4	164
112	Elevated Neuronal Expression of CD200 Protects Wlds Mice from Inflammation-Mediated Neurodegeneration. American Journal of Pathology, 2007, 170, 1695-1712.	1.9	141
113	CD11b+Ly-6Chi Suppressive Monocytes in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2007, 179, 5228-5237.	0.4	313
114	Modulating Co-Stimulation. Neurotherapeutics, 2007, 4, 666-675.	2.1	8
115	Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters. Journal of Neuroimmunology, 2006, 177, 151-160.	1.1	19
116	Insights Into the Molecular Pathogenesis of Progression in Multiple Sclerosis. Archives of Neurology, 2006, 63, 25.	4.9	83
117	Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2006, 176, 3480-3489.	0.4	122
118	Protecting Axonal Degeneration by Increasing Nicotinamide Adenine Dinucleotide Levels in Experimental Autoimmune Encephalomyelitis Models. Journal of Neuroscience, 2006, 26, 9794-9804.	1.7	144
119	Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response. Journal of Immunology, 2006, 177, 4196-4202.	0.4	148
120	The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nature Immunology, 2005, 6, 1245-1252.	7.0	1,697
121	Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2005, 164, 10-21.	1.1	266
122	The cell cycle associated protein, HTm4, is expressed in differentiating cellsof the hematopoietic and central nervous system in mice. Journal of Molecular Histology, 2005, 36, 77-87.	1.0	9
123	Corticotropin-Releasing Hormone Contributes to the Peripheral Inflammatory Response in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2005, 174, 5407-5413.	0.4	43
124	A critical role for the programmed death ligand 1 in fetomaternal tolerance. Journal of Experimental Medicine, 2005, 202, 231-237.	4.2	375
125	Kinin B1 Receptor Expression on Multiple Sclerosis Mononuclear Cells. Archives of Neurology, 2005, 62, 795.	4.9	31
126	Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1Â/CXC chemokine receptor 4 pathway. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 18117-18122.	3.3	1,023

#	Article	IF	Citations
127	Defining Th1 and Th2 Immune Responses in a Reciprocal Cytokine Environment In Vivo. Journal of Immunology, 2004, 172, 4260-4265.	0.4	24
128	Assessment by flow cytometry of intracellular cytokine production in the peripheral blood cells of renal transplant recipients. Clinical Transplantation, 2004, 18, 395-401.	0.8	15
129	Magnetic Resonance Imaging Surrogates of Multiple Sclerosis Pathology and Their Relationship to Central Nervous System Atrophy. Journal of Neuroimaging, 2004, 14, 46S.	1.0	11
130	Mutations in ARFGEF2 implicate vesicle trafficking in neural progenitor proliferation and migration in the human cerebral cortex. Nature Genetics, 2004, 36, 69-76.	9.4	340
131	Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-Î³ production of CD8+ T cells in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2004, 146, 189-198.	1.1	45
132	Expression of Cux-1 and Cux-2 in the subventricular zone and upper layers II-IV of the cerebral cortex. Journal of Comparative Neurology, 2004, 479, 168-180.	0.9	461
133	Neural Stem/Progenitor Cells Express Costimulatory Molecules That Are Differentially Regulated by Inflammatory and Apoptotic Stimuli. American Journal of Pathology, 2004, 164, 1615-1625.	1.9	90
134	The Roles of the New Negative T Cell Costimulatory Pathways in Regulating Autoimmunity. Immunity, 2004, 20, 529-538.	6.6	202
135	Cytokine Shifts and Tolerance in Experimental Autoimmune Encephalomyelitis. Immunologic Research, 2003, 28, 223-240.	1.3	57
136	Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. Journal of Neuroimmunology, 2003, 136, 140-148.	1.1	92
137	20. Immunologic neuromuscular disorders. Journal of Allergy and Clinical Immunology, 2003, 111, S659-S668.	1.5	21
138	Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Allergy and Clinical Immunology, 2003, 112, 837-849.	1.5	50
139	The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. Journal of Experimental Medicine, 2003, 198, 63-69.	4.2	697
140	Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis. Journal of Experimental Medicine, 2003, 198, 71-78.	4.2	461
141	T cell costimulatory pathways: blockade for autoimmunity. Expert Opinion on Biological Therapy, 2003, 3, 227-236.	1.4	28
142	Neural Stem Cell Biology May Be Well Suited for Improving Brain Tumor Therapies. Cancer Journal (Sudbury, Mass), 2003, 9, 189-204.	1.0	58
143	Genetic programs and responses of neural stem/progenitor cells during demyelination: potential insights into repair mechanisms in multiple sclerosis. Physiological Genomics, 2003, 14, 171-197.	1.0	38
144	Regulatory functions of CD8+CD28â€“ T cells in an autoimmune disease model. Journal of Clinical Investigation, 2003, 112, 1037-1048.	3.9	236

#	Article	IF	Citations
145	Potential of ??2-Adrenoceptor Agonists as Add-On Therapy for Multiple Sclerosis. CNS Drugs, 2002, 16, 1-8.	2.7	28
146	IL-18 is linked to raised IFN-Î³ in multiple sclerosis and is induced by activated CD4+ T cells via CD40â€“CD40 ligand interactions. Journal of Neuroimmunology, 2002, 125, 134-140.	1.1	82
147	Interferon-Î² treatment alters peripheral blood monocytes chemokine production in MS patients. Journal of Neuroimmunology, 2002, 126, 205-212.	1.1	46
148	T cell costimulatory blockade as a novel immune intervention in autoimmune diseases. Clinics in Dermatology, 2001, 19, 586-591.	0.8	3
149	Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2001, 117, 156-165.	1.1	35
150	Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS. Journal of Neuroimmunology, 2001, 119, 145-149.	1.1	45
151	Specific MDR1 P-Glycoprotein Blockade Inhibits Human Alloimmune T Cell Activation In Vitro. Journal of Immunology, 2001, 166, 2451-2459.	0.4	62
152	CD28-independent induction of experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2001, 107, 575-583.	3.9	69
153	Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. Journal of Clinical Investigation, 2001, 107, 909-916.	3.9	89
154	Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2001, 108, 739-747.	3.9	168
155	Changes in Activated T Cells in the Blood Correlate With Disease Activity in Multiple Sclerosis. Archives of Neurology, 2000, 57, 1183.	4.9	108
156	Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. Journal of Neuroimmunology, 2000, 104, 164-173.	1.1	74
157	Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2000, 105, 1109-1116.	3.9	36
158	The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. Journal of Clinical Investigation, 2000, 106, 63-72.	3.9	125
159	Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 1999, 96, 158-166.	1.1	38
160	Blocking Costimulatory Signals to Induce Transplantation Tolerance and Prevent Autoimmune Disease. International Reviews of Immunology, 1999, 18, 185-199.	1.5	22
161	Pulse Cyclophosphamide Plus Methylprednisolone Induces Myelin-Antigen-Specific IL-4-Secreting T Cells in Multiple Sclerosis Patients. Clinical Immunology and Immunopathology, 1998, 88, 28-34.	2.1	28
162	Seasonal variation of interferon-? production in progressive multiple sclerosis. Annals of Neurology, 1998, 44, 824-828.	2.8	49

#	Article	IF	Citations
163	Immune parameters affecting adenoviral vector gene therapy in the brain. Journal of NeuroVirology, 1998, 4, 194-203.	1.0	33
164	MECHANISMS OF INDIRECT ALLORECOGNITION. Transplantation, 1998, 65, 876-883.	0.5	44
165	THE ROLE OF CTLA4 NEGATIVE SIGNALING PATHWAY IN THE INDUCTION OF ACQUIRED THYMIC TOLERANCE IN VIVO. Transplantation, 1998, 65, S168.	0.5	0
166	Oral Administration of Myelin Induces Antigen-specific TGF-?1 Secreting T Cells in Patients with Multiple Sclerosis. Annals of the New York Academy of Sciences, 1997, 835, 120-131.	1.8	73
167	Oral Administration of Myelin Induces Antigen-specific TGF-?1-secreting T Cells in Multiple Sclerosis Patients. Annals of the New York Academy of Sciences, 1997, 815, 412-422.	1.8	4
168	In VivoMechanisms of Acquired Thymic Tolerance. Cellular Immunology, 1997, 179, 165-173.	1.4	32
169	Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia. Annals of Neurology, 1997, 42, 313-318.	2.8	92
170	Three-year Open Protocol Continuation Study of Oral Tolerization with Myelin Antigens in Multiple Sclerosis and Design of a Phase III Pivotal Trial. Annals of the New York Academy of Sciences, 1996, 778, 243-250.	1.8	26
171	Antigen-specific TGF-Î²1 Secretion with Bovine Myelin Oral Tolerization in Multiple Sclerosis. Annals of the New York Academy of Sciences, 1996, 778, 251-257.	1.8	22
172	Mechanisms of Oral Tolerance by MHC Peptides. Annals of the New York Academy of Sciences, 1996, 778, 338-345.	1.8	24
173	MECHANISMS OF INDIRECT ALLORECOGNITION IN GRAFT REJECTION. Transplantation, 1996, 62, 705-710.	0.5	50
174	Immunogenicity of class II MHC allopeptides in vivo. Human Immunology, 1992, 34, 25.	1.2	0
175	Antigen-Driven Peripheral Immune Tolerance.. Annals of the New York Academy of Sciences, 1991, 636, 227-232.	1.8	29
176	Characterization of immunomodulatory properties and accessory cell function of small intestinal epithelial cells. Cellular Immunology, 1990, 127, 26-34.	1.4	50
177	Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. Cellular Immunology, 1990, 131, 302-310.	1.4	103